# Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

> **NCT05582499** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 716 (estimated)

## Conditions studied

- Breast Neoplasm
- Breast Cancer
- Breast Tumors
- Triple-Negative Breast Cancer (TNBC)
- HER2-positive Breast Cancer
- HER2-negative Breast Cancer
- Hormone Receptor Positive Tumor
- Hormone Receptor Negative Tumor
- Early-stage Breast Cancer
- Locally Advanced Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib
- **DRUG:** Pyrotinib
- **DRUG:** SHR-A1811
- **DRUG:** SHR-1316
- **DRUG:** Camrelizumab
- **DRUG:** SHR-A1921
- **DRUG:** Pertuzumab
- **DRUG:** Trastuzumab
- **DRUG:** Goserelin
- **DRUG:** Letrozole
- **DRUG:** Nab paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Epirubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Fluzoparib
- **DRUG:** Apatinib
- **DRUG:** Famitinib
- **DRUG:** HB1801
- **DRUG:** LEM
- **DRUG:** TQB2102

## Key facts

- **NCT ID:** NCT05582499
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-09
- **Target enrollment:** 716 (ESTIMATED)
- **Last updated:** 2025-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05582499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05582499, "Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05582499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*